news
New data shows benefits of automated blood exchange for sickle cell disease
New studies highlight the potential of automated blood exchange to improve outcomes for sickle cell disease patients.
List view / Grid view
The National Institute for Health and Care Excellence (NICE)
article
The promise of cell therapy: scaling up a new treatment paradigm for hearing loss
Expectations are growing worldwide for discoveries that will harness the potential of cell therapy, which has already brought breakthroughs in therapeutic areas where there is an unmet need, from oncology to ophthalmology and rare disease. In this article, Dr Terri Gaskell, Chief Technology Officer at Rinri Therapeutics, explores some of…
article
Precision medicine beyond oncology
The field of oncology has successfully applied precision medicine approaches to diagnosis and treatment. Success has been driven by a growing understanding of the underlying biology of cancer; the emergence of innovative tools and technologies for biomarker identification and detection; and considerable advocacy by patients, physicians and policymakers that has…
news
Universities collaborate on NIHR’s £1.5million antibiotic resistance study
University of Warwick expertise is contributing to a world-first £1.5million study aiming to tackle one of the biggest public health threats we face - antibiotic resistance.
article
IVF babies: Easy as 1, 2…3?
3 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The ethics of three parent babies has been widely debated - should it be used to save children from deadly mitochondrial diseases or are scientists "playing God"? Here's everything you need to know to decide...
news
NICE supports NHS England’s perinatal mental health initiative
24 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Professor Mark Baker, Director of Guidelines at NICE, said, “Having a baby is a time of huge change and any woman can find herself needing help...
news
NICE issues guidance on biologic treatments for ulcerative colitis
26 February 2015 | By MSD
Expansion in treatment options for moderately to severely active disease allows patients access to REMICADE® (infliximab), SIMPONI® (golimumab) and Humira® (adalimumab)...
news
UK patients with moderately to severely active ulcerative colitis gain access to a range of biologic therapies on the NHS
8 January 2015 | By MSD
NICE says ‘yes’ to REMICADE® (infliximab), HUMIRA® (adalimumab) and SIMPONI® (golimumab) for adult patients with moderately to severely active ulcerative colitis...